Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Example of QFR technology, which uses a rotation of the C-arm around the patient to create a 3D model and a color coded map showing the FFR values and drops in blood flow.

FFR-angiography guided lesion selection for PCI improves two-year outcomes in TCT late-breaker

Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.

September 27, 2022
High-risk percutaneous coronary intervention (PCI) with an Impella heart pump is associated with better outcomes, including a significantly higher survival rate, than high-risk PCI with an intra-aortic balloon pump (IABP), according to new findings published in the American Journal of Cardiology. Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Regulatory Roundup: FDA clears AI model for RV/LV ratios, approves calcium-blocking TAVR valve and much more

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

September 23, 2022
Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD trial prsented at SCAI 2022. #DisruptPAD, #DisruptCAD, #SCAI #SCAI22 #SCAI2022

Is IVL equally effective in male and female patients? Shockwave Medical aims to find out with a historic new study

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

September 22, 2022
Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology. #TEER #TMVR

MitraClip and TriClip TEER devices continue to show positive results

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

September 21, 2022
The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

September 21, 2022
Medtronic launches Evolut FX TAVR system aortic stenosis.

Medtronic launches Evolut FX TAVR system for severe aortic stenosis

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

September 20, 2022
The Pascal transcatheter mitral valve repair system. Similar to the latest version of the MitraClip, the Pascal can operate each leaflet independently to grasp the mitral valve leaflets. Results of the CLASP IID trial at #TCT2022.

Pascal transcatheter mitral repair device performs as well as MitraClip in late-breaking CLASP IID Trial 

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.

September 20, 2022
Positive data was presented on the first-generation Symplicity (left) long-term outcomes and from the Recor ultrasound renal denervation system pivotal trial at TCT 2022. #TCT #TCT2022

Renal denervation lowered blood pressure in two late-breaking TCT trials 

Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.

September 19, 2022
Displaying 337 - 344 of 1371

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup